Cinfa Opens up a New Direction with New Product Launch

H. pylori is the main cause of gastritis, peptic ulcers, and stomach cancer. In the domestic health care market, there is a scarcity of functional products such as “anti-H. pylori”, and Cinfa has taken the lead in this field to open up a new direction in the health market. When diagnosed with H. pylori infection, most people use antibiotic treatment, which kills H. pylori and intestinal beneficial bacteria at the same time, easily leading to intestinal flora dysbiosis. Therefore, Cinfa, a global pharmaceutical company from Spain, has selected the highly representative probiotics “Saccharomyces boulardii + Lactobacillus royi” from clinical trials as a key combination for adjuvant therapy and has launched capsules to combat H. pylori. (Source: